Linked Life Data

11710283

Source:http://linkedlifedata.com/resource/pubmed/id/11710283

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-11-16
pubmed:abstractText
Twenty seven breast cancer patients with receptor-positive tumors stage IIb-IIIa (TNM) were treated with an aromatase inhibitor--letrozole, 2.5 mg/day, or an antiestrogen--tamoxifen, 20 mg/day, 4 months before surgery. Complete or partial response (CP + PR) was recorded in patients older than those with stabilization or progression of the disease. Moreover, the former group tended to show higher of suppression of blood-estradiol and progesterone receptors levels in tumor and lower suppression of serum-FSH concentration after treatment. These, practically, first findings of the kind suggest that the search for hormonal markers to predict the efficiency of neoadjuvant hormonal therapy for breast cancer should be continued.
pubmed:language
rus
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0507-3758
pubmed:author
pubmed:issnType
Print
pubmed:volume
47
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
425-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
[Interrelationship between response to neoadjuvant hormone therapy and hormonal-metabolic status in breast cancer patients].
pubmed:affiliation
N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
pubmed:publicationType
Journal Article, English Abstract